Publications by authors named "Thomas Michaeli"

Claim this Profile
V
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.
Daniel Tobias Michaeli, Thomas Michaeli

Pharmacoeconomics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Daniel Tobias Michaeli

Breast Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Healthcare Workforce Shortage of Nurses and Physicians: Practice, Theory, Evidence, and Ways Forward.
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Thomas Michaeli

Policy Polit Nurs Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli

BMJ Evid Based Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli

Eur J Health Econ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.
Thomas Michaeli, Daniel Tobias Michaeli

Value Health· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
Daniel Tobias Michaeli, Thomas Michaeli

J Natl Compr Canc Netw· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli

J Natl Cancer Inst· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Daniel Tobias Michaeli, Thomas Michaeli

Pharmacoeconomics· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
Daniel Tobias Michaeli, Thomas Michaeli

Value Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, Thomas Michaeli

Am J Cardiovasc Drugs· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells.
Julia Caroline Michaeli, Sebastian Albers, Carolina de la Torre, Yannick Schreiner, Sara Faust, Thomas Michaeli, Daniel Tobias Michaeli

Sci Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli

Cardiovasc Drugs Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in cancer therapy: clinical benefit of new cancer drugs.
Daniel Tobias Michaeli, Julia Caroline Michaeli, Thomas Michaeli

Aging (Albany NY)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli

BMJ· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
Daniel Tobias Michaeli, Thomas Michaeli

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value drivers of development stage biopharma companies.
Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli

Eur J Health Econ· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Daniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli, Aurelio Miracolo, Panos Kanavos

Invest New Drugs· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli

Clin Drug Investig· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socio-economic burden of disease: Survivorship costs for bladder cancer.
Julia Caroline Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli, Daniel Tobias Michaeli

J Cancer Policy· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socio-economic burden of disease: Survivorship costs for renal cell carcinoma.
Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli

Eur J Cancer Care (Engl)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
Daniel Tobias Michaeli, Sophia Stoycheva, Simon Mashudu Marcus, Wenjia Zhang, Julia Caroline Michaeli, Thomas Michaeli

Clin Drug Investig· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors.
Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli

Ther Innov Regul Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical education and mental health during COVID-19: a survey across 9 countries.
Daniel Michaeli, Gregory Keough, Francisco Perez-Dominguez, Francisca Polanco-Ilabaca, Fernanda Pinto-Toledo, Julia Michaeli, Thomas Michaeli

Int J Med Educ· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis